At a glance
ClinicalIndex Comparison RecordPhase 1Withdrawn· 0 enrolled
Drug / intervention
Erwinia Chrysanthemi asparaginasedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older
In Brief
A Phase 1 clinical trial evaluating Erwinia Chrysanthemi asparaginase for Acute Lymphoblastic Leukemia (ALL) and 2 related conditions. Withdrawn before enrollment, across 1 site.
Signals
Trial was withdrawn before enrollment
Detailed Summary
The purpose of this study is to test the safety of Erwinia Chrysanthemi asparaginase when used alone and together with chemotherapy and find out what effects, if any, it has on people.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Lymphoblastic Leukemia (ALL), Newly Diagnosed Philadelphia Chromosome Negative, Aged 60 Years or Older
CountriesUnited States
CollaboratorsJazz Pharmaceuticals
Timeline
Phase 1WithdrawnFinished
20162017201820192020202120222023202420252026
Enrollment StartJan 2016
First PostedJan 2016
Primary CompletionJun 2017
TodayJul 2026
First PostedJan 6, 2016
Enrollment StartJan 1, 2016
Primary CompletionJun 1, 2017
TodayJul 1, 2026
Enrollment to primary: 1.4 yearsPosted 10.5 years ago
Interventions
Erwinia Chrysanthemi asparaginasedrug